ArticlePrzeglad gastroenterologiczny2026
Effectiveness of curcumin in achieving clinical remission and reducing disease activity in ulcerative colitis: a randomised, controlled trial.
Article in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ulcerative colitis (UC) is a chronic inflammatory condition affecting the inner lining of the colon. For patients with mild to moderate symptoms who do not improve with optimised mesalamine therapy, corticosteroids or immunomodulators may be necessary, although these options carry a risk of significant side effects. Aim: Our study evaluated the efficacy of curcumin in achieving clinical remission and reducing disease severity in UC patients. Material and methods: In this clinical trial, patients diagnosed with mild-to-moderate UC were randomised into a control group ( Results: Per-protocol analysis revealed significantly greater improvement in the curcumin therapy group compared to controls (-2.76 vs. -0.87; Conclusions: We demonstrated that a two-month curcumin therapy regimen of 2 g daily is ineffective in reducing disease severity in patients with mild-to-moderate UC. However, patients in the curcumin therapy group showed greater improvement compared to the control group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.